Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON-HF trial.
Humans
Stroke Volume
Heart Failure
/ drug therapy
Angiotensin Receptor Antagonists
/ therapeutic use
Aftercare
Tetrazoles
/ therapeutic use
Angiotensin-Converting Enzyme Inhibitors
/ therapeutic use
Patient Discharge
Aminobutyrates
/ therapeutic use
Valsartan
/ therapeutic use
Biphenyl Compounds
/ therapeutic use
Hospitalization
Drug Combinations
Kidney
/ physiology
Heart failure with preserved ejection fraction
Hospitalization
Kidney function
Sacubitril/valsartan
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
11
07
2022
received:
30
04
2022
accepted:
18
07
2022
pubmed:
28
7
2022
medline:
29
11
2022
entrez:
27
7
2022
Statut:
ppublish
Résumé
Worsening renal function may impact long-term outcomes in heart failure (HF). However, little is known about the longitudinal trajectories in renal function in relation to HF hospitalization or how this high-risk clinical event impacts renal outcomes. In PARAGON-HF, we evaluated the association between recency of prior HF hospitalization (occurring pre-randomization) and subsequent first renal composite outcome: (i) time to ≥50% decline in estimated glomerular filtration rate (eGFR); (ii) development of end-stage renal disease; or (iii) death attributable to renal causes. A total of 2306 (48.1%) patients had a history of prior HF hospitalization. Incident rates of the renal outcome were highest in those most recently hospitalized and decreased with longer time from last hospitalization. Treatment effect on the renal outcome of sacubitril/valsartan versus valsartan was similar between patients with (hazard ratio [HR] 0.43; 95% confidence interval [CI] 0.24-0.76) and without (HR 0.63; 95% CI: 0.33-1.18; p Heart failure hospitalization denotes increased risk for kidney disease progression which continues following recovery from HF decompensation in patients with HF with preserved ejection fraction. PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in HF with Preserved Ejection Fraction), ClinicalTrials.gov NCT01920711.
Identifiants
pubmed: 35895867
doi: 10.1002/ejhf.2638
pmc: PMC10086974
doi:
Substances chimiques
sacubitril
17ERJ0MKGI
Angiotensin Receptor Antagonists
0
Tetrazoles
0
Angiotensin-Converting Enzyme Inhibitors
0
Aminobutyrates
0
Valsartan
80M03YXJ7I
Biphenyl Compounds
0
Drug Combinations
0
Banques de données
ClinicalTrials.gov
['NCT01920711']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1906-1914Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Eur J Heart Fail. 2022 Apr;24(4):653-656
pubmed: 35218135
J Am Heart Assoc. 2018 Aug 7;7(15):e008789
pubmed: 30371240
N Engl J Med. 2014 Apr 10;370(15):1383-92
pubmed: 24716680
J Am Coll Cardiol. 2021 Jul 27;78(4):330-343
pubmed: 33989713
Circ Heart Fail. 2014 Nov;7(6):895-902
pubmed: 25326006
Nat Rev Cardiol. 2015 Apr;12(4):220-9
pubmed: 25666406
JAMA Cardiol. 2021 Jan 1;6(1):68-77
pubmed: 33206129
Circulation. 2007 Sep 25;116(13):1482-7
pubmed: 17724259
JACC Heart Fail. 2017 Jul;5(7):471-482
pubmed: 28662936
Eur Heart J. 2014 Feb;35(7):455-69
pubmed: 24164864
Circulation. 2020 Sep 29;142(13):1236-1245
pubmed: 32845715
N Engl J Med. 2019 Oct 24;381(17):1609-1620
pubmed: 31475794
N Engl J Med. 2021 Oct 14;385(16):1451-1461
pubmed: 34449189
J Am Coll Cardiol. 2020 Jan 28;75(3):245-254
pubmed: 31726194
Arch Intern Med. 2008 Feb 11;168(3):316-24
pubmed: 18268174
Eur J Heart Fail. 2020 Apr;22(4):584-603
pubmed: 31908120
J Am Coll Cardiol. 2018 Jul 24;72(4):351-366
pubmed: 30025570
Circulation. 2020 Jul 21;142(3):230-243
pubmed: 32486833